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Abstract 
 
Opioid addiction is still an emerging problem worlwide. In this South East Asia region, 
particularly Malaysia, opioid is identified as the main substance of dependency. Due to its 
nestled relationship between Intravascular opiod usage and the seroprevalence of Human 
Immunodeficiency Virus (HIV) in the population, the Malaysian government has adopted 
methadone maintenance therapy (MMT) as one of the harm reduction approaches in curbing 
the problem. Despite evidents of succes, methadone therapy has shown variabilities in terms 
of results and clinical outcomes which is very much dose and adherence dependence. This 
has no doubt suggesting for further research and development of anti-addiction treatment. 
Ibogaine on the other hand is far left behind from the streamline treatment of substance 
addiction though studies keep on showing auspicious results on the clinical use. Ibogaine or 
the name Iboga tabernanthe is one of the African shrubs which is used in ritual of African 
Bwiti Community. Due to its pharmacological properties, it is classified as psychedelic and 
has been used in various countries (Canada, New Zealand, Australia and Africa) to treat drug 
addiction. Pharmacologically, Ibogaine was found to exert its effects at various neurological 
systems including dopaminergic, glutamatergic, serotonergic, nicotinic and colinergic 
pathway as well as receptors including opioid, sigma and neurotransmitters such as gamma 
amino butyric acid (GABA). The mechanism of action is through its active metabolites of 
noribogaine which may act as addiction interrupter. With long half life, it will sustain in the 
blood concentration and prolong the pharmacological effects. In the case of opioid addiction, 
ibogaine exhibits the ability to reduce extracellular level of dopamine in the nucleus 
accumbens and further,  its effects on dopaminergic function are largely regulated by its 
interaction with serotonin receptors. Physical side effects include QT prolongation, ataxia, 
dystonia, nausea, vomiting and light sensitivity. Various clinical and animal studies have 
been conducted worlwide with promising results. This paper will review the feasibility 
evidence of clinical application. 
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1. Introduction 
 
Opioid addiction is still an emerging problem worldwide. Before 1960’s, drug mainly 
opioid addiction was regarded solely as social or personal affliction. In the year 1990’s, Dr 
Alan Leshner, a former director of National Institute for Drug Abuse (NIDA) has once 
described opioid addiction is the illness of the brain with behavioral manifestation [Kreek, 
1993]. This was which later found out that it is far beyond the behavioral or attitude 
connotation which made it classifies now as medical problem that needs medical intervention 
[Kreek, 1993; Tasman, 2008 and Kuehn, 2005]. In Malaysia, due to its proximity with the 
Golden Triangle, drug addiction became very prominent and initiated especially during the 
era of the hippies in 1960’s. The number of opioid addicts are eventually expanding with time 
and in the year 1985, Malaysian Government has announced ‘War against Drug Use’ to 
create awareness and prevention among the public and high risk individual. Three acts- the 
Drugs Dependants (Treatment and Rehabilitation) Act 1983; The Dangerous Drugs (Special 
Preventive Measures) Act 1985; and Dangerous Drugs (Forfeiture of Property) Act 1988 
were legislated in order to curb the spread [Kamaruddin, 2002].    
The negative consequences of such behavior are likely the major concern if not only. 
Many studies have found the association between opioid addiction with uprising of 
socioeconomic burden such as criminal cases and loss of productivity [Gossop et al., 2005 
and Tami et al., 2001]. The population is also expected to experience a poor health condition 
with frequent hospitalization, shorter life expectancy [Marlott et al., 1988 and Stanton et al., 
1997] and having infected with various contagious diseases such as hepatitis, endocarditis 
and AIDS [D’Aquila & Williams, 1987; Mascola et al., 1989; Schrager et al., 1991; Des 
Jarlais et al., 2003; Aceijas et al., 2004; Scorzelli, 1988; Chawarski et al., 2006 and Mazlan 
et al., 2006].  
As noticed, those untoward consequences do not only affecting the said population 
but also their family members and community as a whole [Scorzelli, 1992; Rusdi, 2008 and 
UNODC, 2011]. With these justifications, it is important to establish and further develop the 
appropriate treatment approaches specifically meant for the illness. 
 
2. Current treatments available 
 
Many drugs have actually been introduced in the market for such purpo;se namely 
buprenorphine (partial agonist of opioid receptors), naltrexone (opioid receptor antagonist) 
and methadone (full opioid receptor agonist). Methadone as maintenance therapy is 
categorized as one of the harm reduction approaches, whereas buprenorphine and naltrexone 
are aiming for total abstinence. In Malaysia, methadone maintenance therapy (MMT) was 
adopted since 2005 by the Ministry of Health, Malaysia with its main intention to avoid risky 
behavior such as the sharing of syringe, needle and other injecting apparatus [Gossop, 2001]. 
The service is eventually expanding with time, not only among the government run 
healthcare facilities, but also in the private clinics. As it requires life-long commitment from 
the patients and the practitioners, a specific guideline was developed in hand warranting 
proper clinical use and monitoring procedures [MOH Malaysia Methadone Guideline, 2005]. 
Buprenorphine is not widely used mainly due to its high cost and high tendency of abuse 
[Barrett et al., 2001; AT Forum and Donaher & Welsh, 2006]. Naltrexone is the opioid 
antagonist but the usage is not that popular and poor compliance is common [Gerra et al., 
2000].    
With regards to alternative medicine like herbal medicine, mitragynine sp, one of the 
herbs available in Malaysia which has been extensively studied for the last 10 years. 
However, the evidence for clinical use is not that promising [Assangkornchai et al., 2007 and 
Ulbritch et al., 2013]. Ibogaine on the other hand has far left behind from the main stream 
treatment of opioid addiction though preliminary studies keep on showing promising results 
[Bastiaans, 2004; Alper et al., 2008; Donelly, 2011]. This article will briefly review the 
addiction interrupter properties of ibogaine and evidence on how it can be used clinically 
with its studied safety profile. 
 
2.1 About Ibogaine : History and Pharmacological Studies 
 
Ibogaine or the name Iboga tabernanthe is one of the naturally found African shrubs 
which was originally used in the ritual ceremony of African Bwiti Community [Donelly, 
2011]. Based on its pharmacological properties, it is classified as psychedelics and has been 
used in many countries (Canada, New Zealand, Australia and Africa) to treat drug addiction 
[Alper et al., 2008]. 
Currently, Ibogaine is widely known as anti-addiction drug with addiction interrupter 
properties. It helps in decreasing the self-administration of multiple drugs abuse. For an 
example, Ibogaine was found to interrupt the cravings for alcohol, cocaine and opiates, thus 
reduces the addiction of those substances. Not only that, Ibogaine was also found to exert the 
anti-nicotine properties [Popik et al., 1995]. Pharmacologically, Ibogaine was found to exert 
its effects at various neurological systems including dopaminergic, glutamatergic, 
serotonergic, nicotinic and colinergic pathway as well as receptors including opioid, sigma 
and neurotransmitters such as gamma amino butyric acid (GABA).  
The main mechanism of action is through its active metabolites of noribogaine which 
may sustained the blood concentration and prolong the effects of ibogaine [Brown, 2013]. 
In the case of opioid addiction, it shows that ibogaine does have an inhibitory effect on opioid 
withdrawal symptoms and suggests that the complex process resulting in morphine 
withdrawal includes an ibogaine-sensitive functional and transitory alteration of NMDA 
receptor (non-competitive NMDA antagonist). Ibogaine was also found to exhibits the ability 
to reduce extracellular level of dopamine in the nucleus accumbens and further, its effects on 
dopaminergic function are largely regulated by its interaction with serotonin receptors [Popik 
et al., 1995]. 
Moreover, there is a detailed account on serotonin and dopamine involvement in the 
mechanism of action by ibogaine that has been done. Ibogaine has been shown to inhibit 
serotonin transporter (SERT) noncompetitively, in contrast to all other known inhibitors, 
which are competitive with substrates only. Ibogaine binding to SERT increases accessibility 
in the permeation pathway connecting the substrate-binding site with the cytoplasm. Since 
there are some structural similarity between ibogaine and serotonin, it had been suggested 
that ibogaine binds to the substrate site of SERT. The results show that ibogaine binds to a 
distinct site, accessible from the cell exterior only, to inhibit both serotonin transport and 
serotonin-induced ionic currents, including the homologous dopamine transporter (DAT). 
Thus, there is an increase in accessibility of the DAT cytoplasmic permeation pathway too. 
Plus, ibogaine does not inhibit the receptors by forming a long-lived complex with SERT, but 
rather binds directly to the transporter in an inward-open conformation (Brown, 2013; 
Bulling & Schicker, 2012). 
In animal study, the toxicity level of ibogaine and noribogaine has been determined. 
The median lethal dose (LD50) of ibogaine and noribogaine equals to 263 mg and 630 mg/kg 
of mouse body mass, respectively. The toxicity of ibogaine is 2.4 times higher than that of 
noribogaine. Low doses of ibogaine and noribogaine had no impact on the mouse behavior. 
External effects including convulsions, nervous behaviour, limb paralysis were observed only 
when substances were administrated at higher doses [Xu et al., 2000].  
Anecdotal and small scale study has been conducted previously with promising 
results. Clinically, the recommended dose is 15-20mg/kg where the most effective dose was 
found to be between 17-19mg/kg and only two doses at most are needed. Physical side effects 
include ataxia, dystonia, nausea, vomiting and light sensitivity [Donelly, 2013]. Controlled 
clinical trial to date has never carried out because of serious side effects and fatalities 
reported. Concern about the human safety and lack of solid data from human study has 
hampered the progress of development for clinical use [Alper et al., 2008]. 
There was a study conducted involving 33 patients performed in non-medical settings 
under open label conditions with average daily intravenous use of heroin was 0.64±0.5grams. 
Single dose of ibogaine administered has resulted in the resolution of the signs of opioid 
withdrawal without further drug seeking behavior within 24 hours in 25 patients. The effect 
was eventually sustained for another 72 hours post treatment observation. However, the study 
suggested for further clinical investigations in clinical research setting [Alper et al., 1999]  
  
2.2       Safety issues of ibogaine 
 
There were quite a number of reported cases of death or life-threatening 
complications especially the QT prolongation effects [Koenig et al., 2013]. However, the 
approach towards those reported cases should always case-by case basis in order to rationally 
weight between the risks and benefits of ibogaine in clinical setting. One reported case 
suggestive for interaction between methadone and ibogaine progressing patient to QT 
prolongation and end of life. Others reported death in patient who took ibogaine with 
underlying medical problem of liver cirrhosis. This is especially true in patients with chronic 
alcohol ingestion. Overdose of opioids, alcohol and even ibogaine itself may also contribute 
to the incidence of cardiotoxicity [Vlandeeren et al., 2014; Asua, 2013 and Papadodima et 
al., 2013].  
 
3. Summary 
 
To summarize, though it is understood that ibogaine may produce toxicity, this must 
not disguise its potential and hinder further clinical investigations.   The reported cases of 
toxicity is the evident of:- 1) Close monitoring is a must during the treatment; 2) Health 
screening and underlying disease especially related to heart and liver must be ruled out prior 
to treatment; 3) Concomitant drug use must be avoided pre and post treatment and 4) The 
main concern is to legalize the drug under supervised environment.  
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